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coronary artery disease (CAD) undergoing percutaneous coro-
nary intervention (PCI) were electively treated with SES or BMS
(sequential control design). Baseline socio-demographic and
coronary risk factors, major adverse coronary events (MACE),
including death, myocardial infarction, coronary artery bypass
surgery and re-PCI in target vessel, as well as disease-related
direct and indirect costs were documented by standardised ques-
tionnaires completed by patients and physicians through 18
months following PCI. All results are adjusted for age, gender,
household status, 3-vessel heart disease and number of stents.
P-values are from tests of interaction. RESULTS: From April
2003 to June 2005, 658 patients were treated with SES (87%
male, mean age 63  9, 24% diabetic) and 294 patients with
BMS (79% male, mean age 64  10, 20% diabetic). After 18
months, 23% of SES and 27% of BMS patients with diabetes had
suffered MACE in comparison to 9% of SES and 18% of BMS
patients without diabetes (no signiﬁcant difference in the effect of
SES in the presence of diabetes, adjusted = 0.354). In diabetic
patients, SES and BMS incurred total costs of EUR 14,357
and 10,909, respectively. In non-diabetic patients, SES and
BMS costs totalled EUR 13,241 and 11,215, respectively (p
adjusted = 0.164). In diabetic patients, the cost-effectiveness of
SES vs. BMS was EUR 92,400 per patient free from MACE and
in non-diabetic patients, EUR 16,163. CONCLUSIONS: In this
subgroup analysis, MACE in patients with diabetes did not
appear to be inﬂuenced by stent type, whereas in non-diabetic
patients SES use resulted in lower MACE. SES implantation was
less cost-effective in patients with diabetes than in non-diabetic
patients.
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OBJECTIVES: Use of niacin extended-release with statin mono-
therapy (SM) for combined lipid target attainment (CLTA) of
LDL-C, HDL-C, and triglycerides (TG) has been limited. The
objective was to compare real-world CLTA among patients
receiving niacin extended-release+any statin (NER+S) versus
ﬁxed-dose simvastatin+ezetimibe (S+E) combination therapy.
METHODS: A retrospective analysis was conducted on patients
aged 18 years, newly initiating NER+S or S+E therapy between
July 1, 2000–June 30, 2006 (index date), with health plan eligi-
bility of at least 12 months pre- and post-index date, and at
non-target HDL-C (<40 mg/dL) and TG levels (>150 mg/dL) at
index date using a large integrated research claims database.
CLTA, assessed at the last laboratory visit within 12 months of
index date, was deﬁned according to NCEP ATP III, ADA, and
AHA Women’s guidelines where appropriate. A propensity score,
controlling for differences in index date age, gender, LDL-C,
HDL-C, and TG levels, was included as a covariate in a multi-
variate logistic regression model comparing odds of achieving
CLTA between treatment groups. RESULTS: A total of 883
patients were analyzed, 445 initiating NER+S and 438 initiating
S+E. NER+S patients were signiﬁcantly older (54  9 years
vs. 51  8 years; p < 0.0001), more male (81% vs. 55%;
p < 0.0001), hypertensive (80% vs. 67%; p < 0.0001), and with
prior cardiovascular disease (CVD) (46% vs. 17%; p < 0.0001)
than S+E patients. All NER+S patients and some S+E patients
(48%) were prescribed SM prior to index date. Mean baseline
values for LDL-C (98  36 vs. 136  43 mg/dL; p < 0.0001)
and HDL-C (37  9 vs.44  11 mg/dL; p < 0.0001) were signiﬁ-
cantly lower among NER+S patients. Logistic regression analysis
indicated 64% (OR: 1.64; 95% C.I.: 1.02–2.61) increased like-
lihood of CLTA among NER+S patients versus S+E patients.
CONCLUSIONS: Dyslipidemia patients initiating NER+S
therapy were more likely to achieve CLTA than patients initiating
S+E therapy in a real-world setting, thus implying a greater
potential reduction in cardiovascular risk.
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OBJECTIVES: To assess the effectiveness of clopidogrel in addi-
tion to aspirin versus aspirin alone after acute coronary syn-
drome (ACS) in an Australian context. METHODS: A Markov
model was constructed to simulate the onset of major cardiovas-
cular events (composite of myocardial infarction, ischemic stroke
and cardiovascular death), major bleeding events and non-
cardiovascular death in a representative cohort of 1000 subjects
experiencing ACS. In the ﬁrst year post ACS, underlying risks
of events were drawn from the nationwide Australian Acute
Coronary Syndromes Prospective Audit (ACACIA) registry
(n = 2553). In subsequent years, risks from Australian partici-
pants of the Reduction in Atherothrombosis for Continued
Health (REACH) registry (n = 2567) were used. Decision analy-
sis compared the two interventions and follow-up was simulated
for ten years. Relative risks of cardiovascular and bleeding events
associated with clopidogrel were drawn from the Clopidogrel in
Unstable Angina to Prevent Recurrent Events (CURE) trial, and
assumed to be sustained as long as subjects remained on treat-
ment. Uncertainty analyses were undertaken via Monte Carlo
simulation. RESULTS: The modeled outcomes from the simu-
lated follow-up of 1000 subjects in the ten year model were
major CV events, major bleeding events and deaths. There were
fewer CV events and deaths in the clopidogrel arm but more
bleeding events than aspirin. The number needed to treat (NNT)
to avoid a major CV event was 14 (9–29); to avoid a death was
33 (14–207). Overall, there were 8413 life years gained in clo-
pidogrel compared with 8191 in aspirin alone. CONCLUSIONS:
In the simulated cohort, the addition of clopidogrel to aspirin
represents a highly effective strategy for the secondary prevention
of death and cardiovascular events following ACS. Although
there is a small increase in bleeding in the simulated cohort, the
net effect remains a signiﬁcant prevention of cardiovascular
events, saving of lives and years of life gained.
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OBJECTIVES: The aim of this systematic review (SR) is to
compare efﬁcacy and safety of bosentan, epoprostenol, iloprost,
sildenaﬁl and treprostinil with conventional treatment (CT)
in patients with pulmonary arterial hypertension (PAH).
METHODS: Analysis was performed according to “Polish
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